The agreement grants the Japanese pharma the worldwide license to initially use Sangamo's proprietary neurotropic ...

Astellas Pharma and Sangamo Therapeutics have signed a licence agreement for a neurotropic adeno-associated virus (AAV) ...

Astellas Pharma partners with Sangamo Therapeutics to license STAC-BBB, a neurotropic AAV capsid for neurological disease ...

Astellas signs license agreement with Sangamo Therapeutics to deliver genomic medicines for neurological diseases: Tokyo and Richmond, Calif Saturday, December 21, 2024, 10:00 Hrs ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) Thursday said it has signed an agreement with Sangamo Therapeutics, Inc. (SGMO) to leverage Sangamo's proprietary neurotropic adeno-associated virus (AAV) ...

“Astellas”), today announced they have entered into a license agreement allowing Astellas to leverage Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC ...